GlaxoSmithKline has rejected a £50bn bid from Unilever to acquire its consumer health joint venture with Pfizer, saying it “fundamentally undervalued” the business and its future prospects.
葛蘭素史克(GlaxoSmithKline, GSK)拒絕了聯合利華(Unilever)以500億英鎊收購其與輝瑞(Pfizer)的消費者健康合資企業的報價，稱此舉「從根本上低估了」該業務及其未來前景。
您已閱讀5%（290字），剩餘95%（5833字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。